Expedite your nonfiction book discovery process with Readara interviews, summaries and recommendations, Broaden your knowledge and gain insights from leading experts and scholars
In-depth, hour-long interviews with notable nonfiction authors, Gain new perspectives and ideas from the writer’s expertise and research, Valuable resource for readers and researchers
Optimize your book discovery process, Four-to eight-page summaries prepared by subject matter experts, Quickly review the book’s central messages and range of content
Books are handpicked covering a wide range of important categories and topics, Selected authors are subject experts, field professionals, or distinguished academics
Our editorial team includes books offering insights, unique views and researched-narratives in categories, Trade shows and book fairs, Book signings and in person author talks,Webinars and online events
Connect with editors and designers,Discover PR & marketing services providers, Source printers and related service providers
A New York Times Notable Book
A Washington Post Notable Book
One of the Best Books of the Year: NPR, San Francisco Chronicle, Time, Esquire, Fortune, Marie Claire, GQ, Mental Floss, Science Friday, Bloomberg, Popular Mechanics, BookRiot, The Seattle Times, The Oregonian, Publishers Weekly, Library Journal
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup unicorn promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings--from journalists to their own employees.
Rigorously reported and fearlessly written, Bad Blood is a gripping story of the biggest corporate fraud since Enron--a tale of ambition and hubris set amid the bold promises of Silicon Valley.
John Carreyrou, a two-time Pulitzer Prize winner, was a reporter at The Wall Street Journal for twenty years. For his extensive coverage of Theranos, Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism in the category of beat reporting, and the Barlett & Steele Silver Award for Investigative Business Journalism. Bad Blood was named the Financial Times and McKinsey Business Book of the Year. Carreyrou lives in Brooklyn, New York, with his wife and three children.
Source: Penguin Random House
No Community reviews